{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:05:12Z","timestamp":1794128712937,"version":"4.8.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL16108 7"],"award-info":[{"award-number":["1R01HL16108 7"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R24EY028767"],"award-info":[{"award-number":["R24EY028767"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["RO1EY025794"],"award-info":[{"award-number":["RO1EY025794"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1P01AG071463"],"award-info":[{"award-number":["1P01AG071463"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC-1479"],"award-info":[{"award-number":["CRC-1479"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["441891347"],"award-info":[{"award-number":["441891347"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KI1795\/2-1"],"award-info":[{"award-number":["KI1795\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006696","name":"New York Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002714","name":"University of Freiburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jcyt.2023.01.015","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T08:12:11Z","timestamp":1677658331000},"page":"782-788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa"],"prefix":"10.1016","volume":"25","author":[{"given":"Kathrin","family":"Dieter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7846-3388","authenticated-orcid":false,"given":"Elke","family":"Niebergall-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Fluhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha Y.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Ganss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Kiritsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1312-0488","authenticated-orcid":false,"given":"Markus H.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-4645","authenticated-orcid":false,"given":"Mark A.","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2023.01.015_bib0001","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","article-title":"Epidermolysis bullosa","volume":"6","author":"Bardhan","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0002","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.jaad.2020.08.118","article-title":"Classification of 2 distinct wound types in recessive dystrophic epidermolysis bullosa: A retrospective and cohort natural history study","volume":"85","author":"Solis","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0003","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jaad.2020.03.028","article-title":"Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey","volume":"85","author":"Eng","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104479","article-title":"Persistent release of IL-1s from skin is associated with systemic cardio-vascular disease, emaciation and systemic amyloidosis: The potential of anti-IL-1 therapy for systemic inflammatory diseases","volume":"9","author":"Yamanaka","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0005","first-page":"961","article-title":"Canakinumab in recessive dystrophic epidermolysis bullosa: A novel unexpected weapon for non-healing wounds?","volume":"34","author":"Annicchiarico","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0006","doi-asserted-by":"crossref","first-page":"47156","DOI":"10.1074\/jbc.M308700200","article-title":"Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter","volume":"278","author":"Frank","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0007","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/stem.3356","article-title":"ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment","volume":"39","author":"Riedl","year":"2021","journal-title":"Stem Cells"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0008","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/stem.3022","article-title":"Newly defined ATP-binding cassette subfamily B member 5 positive dermal mesenchymal stem cells promote healing of chronic iron-overload wounds via secretion of interleukin-1 receptor antagonist","volume":"37","author":"Vander Beken","year":"2019","journal-title":"Stem Cells"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0009","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jcyt.2020.08.012","article-title":"Ex vivo-expanded highly pure ABCB5(+) mesenchymal stromal cells as Good Manufacturing Practice\u2013compliant autologous advanced therapy medicinal product for clinical use: Process validation and first in-human data","volume":"23","author":"Kerstan","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100067","article-title":"Allogeneic ABCB5(+) mesenchymal stem cells for treatment-refractory chronic venous ulcers: A phase I\/IIa clinical trial","volume":"2","author":"Kerstan","year":"2022","journal-title":"JID Innovations"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0011","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jid.2021.10.026","article-title":"Angiogenin released from ABCB5(+) stromal precursors improves healing of diabetic wounds by promoting angiogenesis","volume":"142","author":"Singh","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0012","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s13287-022-03156-9","article-title":"Translational development of ABCB5+ dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers","volume":"13","author":"Kerstan","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0013","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151922","article-title":"Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa","volume":"6","author":"Kiritsi","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0014","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2013.09.041","article-title":"Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI)","volume":"70","author":"Loh","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/pde.12317","article-title":"Instrument for scoring clinical outcome of research for epidermolysis bullosa: A consensus-generated clinical research tool","volume":"32","author":"Schwieger-Briel","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","article-title":"The challenges of living with and managing epidermolysis bullosa: Insights from patients and caregivers","volume":"15","author":"Bruckner","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0017","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.3390\/jcm10245836","article-title":"Identifying epidermolysis bullosa patient needs and perceived treatment benefits: An explorative study using the patient benefit index","volume":"10","author":"Schr\u00e4der","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0018","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration. Epidermolysis bullosa: Developing drugs for treatment of cutaneous manifestations \u2013 guidance for industry, https:\/\/www.fda.gov\/media\/128419\/download; 2019 [Accessed 16 November 2022]."},{"key":"10.1016\/j.jcyt.2023.01.015_bib0019","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: Chronic cutaneous ulcer and burn wounds \u2013 developing products for treatment, https:\/\/www.fda.gov\/media\/71278\/download; 2006 [Accessed 16 November 2022]."},{"key":"10.1016\/j.jcyt.2023.01.015_bib0020","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s13287-020-01987-y","article-title":"Process data of allogeneic ex vivo-expanded ABCB5+ mesenchymal stromal cells for human use: Off-the-shelf GMP-manufactured donor-independent ATMP","volume":"11","author":"Ballikaya","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0021","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jcyt.2018.12.005","article-title":"In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials","volume":"21","author":"Tappenbeck","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0022","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0023","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaad.2019.11.038","article-title":"Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa","volume":"83","author":"Rashidghamat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0024","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143606","article-title":"Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients","volume":"6","author":"Lee","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0025","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1172\/JCI92707","article-title":"Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients","volume":"127","author":"Woodley","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0026","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130554","article-title":"Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa","volume":"4","author":"Eichstadt","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0027","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jid.2018.03.334","article-title":"50% wound healing correlates with RDEB patient reported outcomes in pain, itch and skin durability","volume":"138","author":"Dutt-Singkh","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0028","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/bjd.12599","article-title":"Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial","volume":"169","author":"Petrof","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0029","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13023-020-01419-3","article-title":"Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: A phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)","volume":"15","author":"Paller","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0030","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13063-019-3362-z","article-title":"Oleogel-S10 Phase 3 study \"EASE\" for epidermolysis bullosa: Study design and rationale","volume":"20","author":"Kern","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0031","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0032","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ajpath.2017.03.003","article-title":"Pathomechanisms of altered wound healing in recessive dystrophic epidermolysis bullosa","volume":"187","author":"Cianfarani","year":"2017","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0033","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.3390\/ijms20225707","article-title":"Epidermolysis bullosa-associated squamous cell carcinoma: From pathogenesis to therapeutic perspectives","volume":"20","author":"Condorelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0034","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/exd.14411","article-title":"Immunological mechanisms underlying progression of chronic wounds in recessive dystrophic epidermolysis bullosa","volume":"30","author":"Huitema","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0035","article-title":"Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: Results from the phase III randomized double-blind phase of the EASE study","author":"Kern","year":"2022","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0036","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13023-020-01435-3","article-title":"Wound closure in epidermolysis bullosa: Data from the vehicle arm of the phase 3 ESSENCE Study","volume":"15","author":"Murrell","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0037","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/pde.14576","article-title":"Clinical characteristics associated with increased wound size in patients with recessive dystrophic epidermolysis bullosa","volume":"38","author":"Solis","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0038","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13023-016-0411-5","article-title":"Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: A multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial","volume":"11","author":"Chiaverini","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0039","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/stem.2417","article-title":"Suppression of neutrophil-mediated tissue damage\u08e7a novel skill of mesenchymal stem cells","volume":"34","author":"Jiang","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/dermatopathology7020007","article-title":"Emaciation, congestive heart failure, and systemic amyloidosis in severe recessive dystrophic epidermolysis bullosa: Possible internal complications due to skin-derived inflammatory cytokines derived from the injured skin","volume":"7","author":"Matsushima","year":"2020","journal-title":"Dermatopathology (Basel)"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0041","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jdermsci.2020.10.009","article-title":"Aberrant recruitment of leukocytes defines poor wound healing in patients with recessive dystrophic epidermolysis bullosa","volume":"100","author":"Phillips","year":"2020","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jcyt.2023.01.015_bib0042","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/dth.12305","article-title":"Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: A randomized controlled trial","volume":"29","author":"El-Darouti","year":"2016","journal-title":"Dermatol Ther"}],"updated-by":[{"DOI":"10.1016\/j.jcyt.2023.06.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000}}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:35:59Z","timestamp":1778614559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324923000361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1465324923000361"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.01.015","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}